Protective efficacy of ursodeoxycholic acid nanoparticles in animal model of inflammatory bowel disease

References

• Agnihotri SA, Aminabhavi TM. Chitosan nanoparticles for prolonged delivery of timolol maleate. Drug Dev Ind Pharm, 2007;33:1254–62
   PubMed Web of Science ®Google Scholar
• Armstrong NA, James KC. 1996. Pharmaceutical experimental design and interpretation. London, UK: Taylor and Francis
   Google Scholar
• Asghar LFA, Chandran S. Multiparticulate formulation approach to colon specific drug delivery: Current perspectives. J Pharm Pharm Sci, 2006;9:327–38
   PubMed Web of Science ®Google Scholar
• Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker. J Invest Dermatol, 1982;78:206–9
   PubMed Web of Science ®Google Scholar
• Bragagni M, Beneitez C, Martín C, Hernán Pérez de la Ossa D, Mura PA, Gil-Alegre ME. Selection of PLA polymers for the development of injectable prilocaine controlled release microparticles: Usefulness of thermal analysis. Int J Pharm, 2013;441:468–75
   PubMed Web of Science ®Google Scholar
• Clemente TR, Dos Santos AN, Sturaro JN, Gotardo EM, de Oliveira CC, Acedo SC, Caria CR, Pedrazzoli J Jr, Ribeiro ML, Gambero A. Infliximab modifies mesenteric adipose tissue alterations and intestinal inflammation in rats with TNBS-induced colitis. Scand J Gastroenterol, 2012;8–9:943–50
   Google Scholar
• Choi G, Lee JH, Oh YJ, Choy YB, Park MC, Chang HC, Choy JH. Inorganic-polymer nanohybrid carrier for delivery of a poorly-soluble drug, ursodeoxycholic acid. Int J Pharm, 2010;402:117–22
   PubMed Web of Science ®Google Scholar
• Christensen FN, Davis SS, Hardy JG, Taylor MJ, Whalley DR, Wilson CG. The use of gamma scintigraphy to follow the gastrointestinal transit of pharmaceutical formulations. J Pharm Pharmacol, 1985;37:91–5
   PubMed Web of Science ®Google Scholar
• Coco R, Plapied L, Pourcelle V, Jérôme C, Brayden DJ, Schneider YJ, Préat V. Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies. Int J Pharm, 2013;440:3–12
   PubMed Web of Science ®Google Scholar
• de Souza Almeida ES, Filho VC, Niero R, Clasen BK, Balogun SO, de Oliveira Martins DT. Pharmacological mechanisms underlying the anti-ulcer activity of methanol extract and canthin-6-one of Simaba ferruginea A. St-Hil in animal models. J Ethnopharmacol, 2011;134:630–6
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollón F, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis, 2010;4:28–62
   PubMed Web of Science ®Google Scholar
• Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S, Brasitus TA. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary Ursodeoxycholic acid. Cancer Res, 1994;54:5071–4
   PubMed Web of Science ®Google Scholar
• Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut, 1988;29:1035–41
   PubMed Web of Science ®Google Scholar
• Ferretti M, Gionchetti P, Rizzello F, Venturi A, Stella P, Corti F, Mizarahi J, Miglioli M, Campieri M. Intracolonic release of nitric oxide during trinitrobenzene sulfonic acid rat colitis. Dig Dis Sci, 1997;42:2606–11
   PubMed Web of Science ®Google Scholar
• Grisham MB, Jourd’Hevil D, Wink DA. Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites: Implications in inflammation. Am J Physiol, 1999;39:15–21
   Google Scholar
• Hardy JG, Davis SS, Khosla R, Robertson CS. Gastrointestinal transit of small tablets in patients with ulcerative colitis. Int J Pharm, 1988;48:79–82
   Web of Science ®Google Scholar
• Hilton JM, Lennard-Jonnes JE, Young AC. A new method for studying the gut transit times using radioopaque markers. Gut, 1969;10:842–7
   PubMed Web of Science ®Google Scholar
• Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: Suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett, 1998;134:129–39
   PubMed Web of Science ®Google Scholar
• Igimi H, Carey MC. pH-Solubility relations of chenodeoxycholic and ursodeoxycholic acids: Physical-chemical basis for dissimilar solution and membrane phenomenon. J Lipid Res, 1980;21:72–90
   PubMed Web of Science ®Google Scholar
• Kemp W. 1996. Organic spectroscopy. Hampshire, UK: Macmillan
   Google Scholar
• Khan AI, Lei L, Norquist AJ, O’Hare D. Intercalation and controlled release of pharceutically active compounds from layered double hydroxides. Chem Commun (Camb), 2001;22:2342–3
   PubMed Web of Science ®Google Scholar
• Khono H, Suzuki R, Yasui Y, Miyamoto S, Wakabayashi K, Tanaka T. Ursodeoxycholic acid verses sulfasalazine in colitis-related colon carcinogenesis in mice. Clin Cancer Res, 2007;13:2519–25
   PubMed Web of Science ®Google Scholar
• Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterol, 1984;87:1344–50
   PubMed Web of Science ®Google Scholar
• Kullmann F, Arndt H, Gross V, Rüschoff J, Schölmerich J. Beneficial effect of ursodeoxycholic acid on mucosal damage in trinitrobenzene sulphonic acid-induced colitis. Eur J Gastroenterol Hepatol, 1997;9:1205–11
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Schäfer U, Lahr C-M. Size-dependant bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res, 2001;18:788–93
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Nanoparticles enhance therapeutic efficacy by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther, 2005;315:196–202
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther, 2001b;299:775–81
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang X, Suwardie H, Wang P, Gogos CG. Miscibility studies of indomethacin and Eudragit® EPO by thermal, rheological, and spectroscopic analysis. J Pharm Sci, 2012;101:2204–12
   PubMed Web of Science ®Google Scholar
• Linehan JD, Kolios G, Valatas V, Robertson DA, Westwick J. Immunomodulatory cytokines suppress epithelial nitric oxide production in inflammatory bowel disease by acting on mononuclear cells. Free Radic Biol Med, 2005;39:1560–9
   PubMed Web of Science ®Google Scholar
• Makharia GK, Ramakrishna BS, Abraham P, Choudhuri G, Misra SP, Ahuja V, Bhatia SJ, Bhasin DK, Dadhich S, Dhali GK, et al.; Indian Society of Gastroenterology Task Force on Inflammatory Bowel Disease. Survey of inflammatory bowel diseases in India. Indian J Gastroenterol, 2012;31:299–306
   PubMedGoogle Scholar
• Martinez-Moya P, Romerio-Calvo I, Requena P, Hernández-Chirlaque C, Aranda CJ, González R, Zarzuelo A, Suárez MD, Martínez-Augustin O, Marín JJ, de Medina FS. Dosedependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol, 2013;15:372–80
   PubMed Web of Science ®Google Scholar
• Mei Q, Xu J-M, Xiang L, Hu Y-M, Hu X-P, Xu Z-W. Change of nitric oxide in experimental colitis and its inhibition by melatonin in vivo and in vitro. Postgrad Med J, 2005;81:667–72
   PubMed Web of Science ®Google Scholar
• Montgomery DC. 2001. Design and analysis of experiments. New York: John Wiley and Sons, INC
   Google Scholar
• Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Walilance JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroentrology, 1989;96:795–803
   PubMed Web of Science ®Google Scholar
• Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Prevention of N-methylnitrosourea-induced colon tumeorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res, 1998;89:1009–13
   PubMedGoogle Scholar
• Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs. Gut, 2001;48:571–7
   PubMed Web of Science ®Google Scholar
• Onishi H, Oosegi T, Machida Y. Efficacy and toxicity of Eudragit-coated chitosan-succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis. Int J Pharm, 2008;358:296–302
   PubMed Web of Science ®Google Scholar
• Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol, 2005;21:408–13
   PubMed Web of Science ®Google Scholar
• Paiva LA, Gurgel LA, Silva RM, Tomé AR, Gramosa NV, Silveira ER, Santos FA, Rao VS. Anti-inflammatory effect of kaurenoic acid, a diterpene from Copaifera langsdorffi on acetic acid induced colitis in rats. Vascul Pharmacol, 2002;39:303–7
   PubMed Web of Science ®Google Scholar
• Patel DM, Patel NM, Patel VF, Bhatt DA. Floating granules of ranitidine hydrochloride-Gelucire 43/01: Formulation optimization using factorial design. AAPS Pharm Sci Tech, 2007;8:E1–7
   PubMedGoogle Scholar
• Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaili L, Refouvelet B, Pellequer Y, Lamprecht A. 5-Amino salicylic acid bound nanoparticles for therapy of inflammatory bowel disease. J Control Release, 2007;123:211–18
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med, 2002;347:417–29
   PubMed Web of Science ®Google Scholar
• Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid based delivery systems. Adv Drug Deliv Rev, 2008;60:673–91
   PubMed Web of Science ®Google Scholar
• Sneydecor GW, Cochran WG. 1989. Factorial experiments. Statistical methods. Iowa: Iowa State University Press
   Google Scholar
• Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut, 2003;52:1587–90
   PubMed Web of Science ®Google Scholar
• Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm, 2006;3:631–43
   PubMed Web of Science ®Google Scholar
• Takagi T, Naito Y, Uchiyama K, Okuda T, Suzuki T, Tsuboi H, Mizushima K, Handa O, Yagi N, Ichikawa H, Yoshikawa T. Colonic insufflation with carbon monoxide gas inhibits the development of intestinal inflammationin rats. Med Gas Res, 2012;2:23. doi: 10.1186/2045-9912-2-23
   PubMedGoogle Scholar
• Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol, 2008;103:3167–82
   PubMed Web of Science ®Google Scholar
• Travis SP, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y, Colombel JF, D'Haens G, Ghosh S, Marteau P, et al. European evidence-based consensus on the management of ulcerative colitis: Current management. J Crohns Colitis, 2008;2:24–62
   PubMed Web of Science ®Google Scholar
• Ventura CA, Tirendi S, Puglisi G, Bousquet E, Panza L. Improvement of water solubility and dissolution rate of ursodeoxycholic acid and chenodeoxycholic acid by complexation with natural and modified β-cyclodextrins. Int J Pharm, 1997;149:1–13
   Web of Science ®Google Scholar
• Watts PJ, Barrow L, Steed KP, Wilson CG, Spiller RC, Melia CD, Davies MC. The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. Int J Pharm, 1992;87:215–21
   Web of Science ®Google Scholar
• USP. 2008. The United States Pharmacopoeial Convention. Rockville, MD: USP
   Google Scholar
• Zhou YH, Yu JP, Liu YF, Teng X-J, Ming M, Lv P, An P, Liu S-Q, Yu H-G. Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-α, NF-κBp65, IL-6) in TNBS-induced colitis in rats mediators of inflammation. Mediators Inflamm, 2006;92642(1–9)
   Google Scholar